>

Aharon Schwartz - CLAL BIOTECHNOLOGY Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>CLA</div>
  Director
Dr. Aharon Schwartz serves as Director at Clal Biotechnology Industries Ltd. since October 16, 2005. Dr. Schwartz currently serves as Chairman of the Board at BioLineRX Ltd. since April 03, 2003. Previously, Dr. Schwartz served at Teva Pharmaceutical Industries Limited as Vice President Strategic Business Planning New Ventures from April 01, 2002 to 2009, as Vice President Global Product Division from 1999 to April 01, 2002, as Vice President Copaxone Division from 1995 to 1999 and as Vice President Business DevelopmentExport Division for from 1993 to 1995
Age: 74  Director Since 2005      
972 3 612 1616  http://www.cbi.co.il
Schwartz has a BS degree in Chemistry and Physics from The Hebrew University of Jerusalem, a MS degree in Chemistry from Technion Israel Institute of Technology and a Doctorate in Philosophy degree in Organic Chemistry from the Weizmann Institute of Science.

Aharon Schwartz Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (5.15) % which means that it has lost $5.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (1.79) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 52.28 M in total debt with debt to equity ratio (D/E) of 6.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. CLAL BIOTECHNOLOGY has Current Ratio of 3.6 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Company Summary

Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.CLAL BIOTECHNOLOGY (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 14 people.

CLAL BIOTECHNOLOGY Leadership Team

Ofer Goldberg, VPView
Sigalia Heifetz, DirectorView
Shmuel Rubinstein, External DirectorView
Tomer Babai, DirectorView
Dafna Gruber, DirectorView
Aharon Schwartz, DirectorView
Gavriel Barabash, DirectorView
Isaac Kohlberg, DirectorView
Nofar Malovani, DirectorView
Assaf Segal, CFOView
Ofer Gonen, Vice PresidentView
Avraham Fischer, Chairman of the BoardView
Yuval Yanai, External DirectorView
Julian Adams, President Chief Scientific OfficerView
Orit Lidor, VP and General CounselView

Stock Performance Indicators

Current Sentiment - CBI

CLAL BIOTECHNOLOGY Investor Sentiment

Most of Macroaxis users are currently bullish on CLAL BIOTECHNOLOGY. What is your opinion about investing in CLAL BIOTECHNOLOGY? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

CLAL BIOTECHNOLOGY Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Dominion Energy and Comp En De. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check out Trending Equities. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.